RecruitingNCT02325674
MEASuRE: Metreleptin Effectiveness And Safety Registry
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amryt Pharma
- Principal Investigator
- Lori HartnettAmryt Pharmaceuticals DAC
- Intervention
- Metreleptin(drug)
- Enrollment
- 100 enrolled
- Eligibility
- All sexes
- Timeline
- 2016 – 2031
Study locations (28)
- University Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope, Duarte, California, United States
- Atlanta Diabetes Associates, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States
- Children's Hospital of New Orleans/LSU Health Sciences Center, New Orleans, Louisiana, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Nih/Niddk/Deob, Bethesda, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Childrens Hospital of Michigan, Detroit, Michigan, United States
- Richmond University Medical Centre, Staten Island, New York, United States
- Endocrinology Research Associates, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02325674 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
See all trials for Lipodystrophy due to peptidic growth factors deficiency →